BIOCQ — Biocept Balance Sheet
0.000.00%
- $0.00m
- -$4.46m
- $25.86m
Annual balance sheet for Biocept, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 3.42 | 9.3 | 14.4 | 28.9 | 12.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.57 | 3.53 | 14.1 | 13.8 | 2.15 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 6.01 | 13.9 | 32.6 | 45.7 | 16.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.74 | 3.84 | 14.4 | 14.3 | 14.1 |
Other Long Term Assets | |||||
Total Assets | 8.75 | 17.7 | 47.5 | 60.4 | 30.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.61 | 5.56 | 12.5 | 11.8 | 5.51 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.71 | 6.53 | 23.8 | 22.9 | 22 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 3.04 | 11.2 | 23.7 | 37.5 | 8.86 |
Total Liabilities & Shareholders' Equity | 8.75 | 17.7 | 47.5 | 60.4 | 30.9 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |